OXT and Prader-Willi syndrome: Preliminary results reported from the phase III CARE-PWS clinical trial indicated beneficial effects of intranasal oxytocin treatment on hunger, anxiety, and obsessive-compulsive behaviors in patients with PWS; however, this finding has not yet been published.